US 12,410,251 B2
ILT-binding agents and methods of use thereof
Dana Yen Mei Duey, San Francisco, CA (US); Allen James Ebens, Jr., San Carlos, CA (US); Daniel David Kaplan, San Mateo, CA (US); Chia-Ying Kao Lam, South San Francisco, CA (US); Kalyani Mondal, San Mateo, CA (US); Geoffrey William Stone, San Francisco, CA (US); and Yan Wang, Foster City, CA (US)
Assigned to NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed by NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Sep. 13, 2023, as Appl. No. 18/466,722.
Application 18/466,722 is a division of application No. 17/244,169, filed on Apr. 29, 2021, granted, now 11,802,155.
Claims priority of provisional application 63/122,848, filed on Dec. 8, 2020.
Claims priority of provisional application 63/019,068, filed on May 1, 2020.
Prior Publication US 2024/0025997 A1, Jan. 25, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. A binding agent that specifically binds human immunoglobulin-like transcript 2 (ILT2) or human immunoglobulin-like transcript 4 (ILT4) comprising:
(i) a heavy chain variable region (VH) comprising a VH-complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:125; and a light chain variable region (VL) comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:126;
(ii) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 127; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 128; or
(iii) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:129; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:130.